Compare Incyte Corporation (INCY) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Progressive Corp — how do they compare? Incyte Corporation trades at $118.01 (market cap $23.11B), while Progressive Corp trades at $206.75 (market cap $123.39B). The key difference: Progressive Corp is far larger — about 5.3× Incyte Corporation's market cap, and Progressive Corp pays a 6.55% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PGR | |
|---|---|---|
Market Cap | $23.11B | $123.39B |
Sector | Health | Financials |
52-Week High | $118.52 | $252.68 |
52-Week Low | $67.38 | $190.40 |
Enterprise Value | $19.13B | $131.61B |
Dividend Yield | — | 6.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PGR trades at $211.22, up 1.57% over 24 hours, with a bearish technical signal but neutral oscillators. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and net income margin expanding to 12.9%. Recent Q2 2026 earnings matched expectations at $4.64 EPS. Analyst consensus price target is $234.56 with 37% buy ratings, though technical resistance looms near $212.
Outlook remains cautiously optimistic given Progressive's earnings consistency and valuation at 10.43 P/E, but risks include competitive pressures and potential earnings volatility. The stock offers value with dividend yield support, though investors should monitor premium growth sustainability amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
